This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Purpose: Primary aims are (1) to determine whether salsalate (a non-steroid anti-inflammatory medication) reduces pain sensitivity in irritable bowel syndrome patients with visceral hypersensitivity, and (2) to select an optimal dose of salsalate for a planned larger study.Secondary aims are (3) to evaluate impact of salsalate on clinical pain, (4) to measure the effects of salsalate on motility, and (5) to compare an empirical measure of perceptual response bias to three questionnaires that are designed to measure hypervigilance for painful somatic sensations.Participants: Subjects will be 24-30 patients with a physician diagnosis of IBS who also fulfill Rome III criteria for IBS diagnosis. (Only 24 are needed for adequate statistical power, but an additional 6 subjects will be recruited to allow for attrition.)Procedures: The design will be a crossover comparing two doses of salsalate and a placebo (capsules only containing lactose) for periods of one week each (a total of three consecutive treatment weeks). At the end of each week of treatment, patients will undergo a barostat test of pain sensitivity.
Showing the most recent 10 out of 782 publications
